


ESPERION UK LIMITED

Annual Report

For the period ended 31 December 2021

Registered number: 13087748





Private and confidential

Registrar of Companies (England and Wales)
Companies House
Crown Way
Cardiff
CF14 3UZ
United Kingdom

18 April 2023

Dear Registrar,

(ESPERION UK LIMITED 13087748)

Please find enclosed the annual accounts of the above-named entity for the year ended 31 December 2021 for processing.

Should you have any difficulties, please return the item for my attention to:

Merchant Square, 20 Wellington Pl, Belfast BT1 6GE.

Should you have any queries, please do not hesitate to contact me.

Yours faithfully,

Christina Kerr

Email: christina.p.kerr@pwc.com

*PricewaterhouseCoopers LLP, Merchant Square, 20 Wellington Pl, Belfast BT1 6GE,
www.pwc.co.uk*

PricewaterhouseCoopers LLP is a limited liability partnership registered in England with registered number OC303525. The registered office of PricewaterhouseCoopers LLP is 1 Embankment Place, London WC2N 6RH. PricewaterhouseCoopers LLP is authorised and regulated by the Financial Conduct Authority for designated investment business and by the Solicitors Regulation Authority for regulated legal activities.

ESPERION UK LIMITED
Company number: 13087748
(the "Company")

Directors' Report
for the period ended 31 December 2021 (the "Report")

The directors presented the Report and the unaudited financial statements for the period from 17 December 2020 to 31 December 2021.

Principal activities

The Company was dormant for the period from 17 December 2020 to 31 December 2021. The Company has not traded since incorporation.

Directors


The directors of the Company who served during the period ended 31 December 2021 and to the date of this report are as follows:

Sheldon Koenig
Benjamin Looker

Auditors

The directors have relied upon the provisions of Sections 475 and 480 of the Companies Act 2006 (the "Act"), which exempt the Company from the obligation to appoint auditors in respect of the period from 17 December 2020 to 31 December 2021.

On behalf of the board

DocuSigned by:


D3CA2D0FDE9B47P.....
Sheldon Koenig

Director

Dated: April 17, 2023

ESPERION UK LIMITED
Company number: 13087748
(the "Company")

Balance sheet
at 31 December 2021

	Notes	2021 £
Current assets		
Cash	2	<u>1</u>
Net assets		<u>1</u>
Capital and reserves		
Called up share capital	3	<u>1</u>
Shareholder funds		<u>1</u>

For the period from 17 December 2020 to 31 December 2021, the Company was entitled to the exemption from audit under section 480 of the Act.


The sole member has not required the Company to obtain an audit in accordance with section 476 of the Act.

The director acknowledges their responsibility for:

- (i) ensuring the company keeps accounting records which comply with sections 386 and 388 of the Act; and
- (ii) preparing accounts which give a true and fair view of the state of affairs of the Company as at the end of the financial period, and of its profit or loss for the financial period, in accordance with section 393, and which otherwise comply with the requirements of the Act relating to accounts, so far as applicable to the Company.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements on pages 2 and 3 were approved by the board of directors on April 17, 2023 and signed on its behalf by:

DocuSigned by:

D3CA2DDF0E3B47F.....
Sheldon Koenig
Director

The notes on page 3 form part of these accounts.

ESPERION UK LIMITED
Company number: 13087748
(the "Company")

/ Notes to the financial statements
for the for the period ended 31 December 2021

1. General

The Company has not prepared a profit and loss account as there was no revenue during the period 17 December 2020 to 31 December 2021; any expenses incurred by the company have been borne by the shareholder.

2. Cash

2021
£

100

3. Share capital

2021
£

Allotted, called up and fully paid
 100 Ordinary shares of £0.01 each

100

4. Directors' emoluments

The directors received no emoluments for the period ended 31 December 2021.

5. Shareholding

The Company's sole shareholder is Esperion Therapeutics, Inc.